On the other hand, pleural effusion localized in an interlobar space is not a common finding, since only 15 cases have been recorded in the literature. 1–11 Multiple, localized pleural effusions ...

Attempts to obliterate the pleural space go back at least as far as 1906, when Spengler 5 instilled silver nitrate in patients with spontaneous pneumothorax. Bethune 6 (1935), Medici 7 (1944) and ...

Lung Therapeutics is developing two primary drugs: LTI-01 to treat loculated pleural effusion, a serious complication of pneumonia, and LTI-03 to treat idiopathic pulmonary fibrosis.

Loculated pleural effusion (LPE) is a condition in which fluid is trapped within the pleural cavity due to fibrinous adhesions, leading to pain, shortness of breath and possibly sepsis.

Chest radiography and computed tomography showed that he had left lower lobe consolidation with a loculated pleural effusion . Pleural fluid analysis was consistent with the diagnosis of empyema ...

Lung Therapeutics announced that it received Orphan Drug Designation for LTI-01, an injectable designed for the treatment of loculated pleural effusion. Lung Therapeutics, a pharmaceutical company ...

The company’s lead drug, LTI-01, is in development for Loculated Pleural Effusion (LPE) and has successfully completed a clinical trial in LPE patients. The company’s ...

“We are pursuing unique, proprietary treatments that eliminate the need for surgery and ineffective off-label drugs for patients with loculated pleural effusion as well as new drugs for fibrosis ...

LTI-01 is in development for loculated pleural effusion ("LPE"), a serious consequence of pneumonia with significant unmet medical need. La historia continúa Second Quarter 2024 Financial Results ...

The Company’s lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).